논문 검색
-
Lenvatinib potentiates the antitumor efficacy of combined radiotherapy and PD-L1 blockade in lung adenocarcinoma.
[BACKGROUND] The potential of Lenvatinib to synergize with combined radiotherapy and immunotherapy in LUAD remains incompletely characterized. [METHODS] We investigated Lenvatinib's effects on radiation-induced PD-L1 in LUAD cells and VEGF…
FULLTEXT: AI-ReML algorithm versus -
Identification of the immune-related diagnostic biomarkers between Graves' disease and thyroid carcinoma based on comprehensive bioinformatics analysis and machine learning.
Increasing evidence suggests that Graves' disease (GD) may increase the risk of thyroid cancer (THCA), but diagnostic biomarkers associated with it remain underexplored. To address this issue, we analyzed the Gene Expression Omnibus (GEO) a…
FULLTEXT: AI-ReML algorithm versus -
The distinct roles of and in proximal- and late-onset colorectal cancer.
Despite the emerging role of the gut microbiome in colorectal cancer (CRC), its significance in early-onset CRC (EOCRC, …
FULLTEXT: AI-ReML algorithm versus -
Adding anti-PD-1 antibody to definitive chemoradiotherapy in elderly patients with esophageal squamous cell carcinoma: higher intensity does not equate to better outcomes.
[BACKGROUND AND PURPOSE] The benefit of adding anti-PD-1 antibodies to definitive chemoradiotherapy (dCRT) in elderly patients with esophageal squamous cell carcinoma (ESCC) remains uncertain. This study evaluated its efficacy and safety ve…
FULLTEXT: AI-ReML algorithm versus -
Economic evaluation of perioperative pembrolizumab plus standard of care as treatment for resectable locally advanced head and neck squamous cell carcinoma in the United States.
[AIMS] In the phase 3 KEYNOTE-689 trial (NCT03765918) among patients with resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC), perioperative pembrolizumab (pembrolizumab before surgery, then continued with standard-…
FULLTEXT: AI-ReML algorithm versus -
Cost-per-responder analysis of TAR-200 versus other Food and Drug Administration-approved novel and generic treatments among patients with Bacillus Calmette-Guérin-unresponsive, high-risk, non-muscle-invasive bladder cancer with carcinoma in situ in the United States.
[AIMS] Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with carcinoma (CIS) is aggressive and treatment options are suboptimal. TAR-200, a novel intravesical drug-releasing system, receiv…
FULLTEXT: AI-ReML algorithm versus -
A real-world study evaluating drug tolerability and health care resource use with acalabrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
[BACKGROUND AND AIM] Bruton tyrosine kinase inhibitors (BTKis) are the standard of care for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Ibrutinib and acalabrutinib are two commo…
FULLTEXT: AI-ReML algorithm versus -
Prolonged progression-free survival with zanubrutinib in relapsed/refractory CLL: an indirect treatment comparison versus other BTK inhibitors using multilevel network meta-regression.
[BACKGROUND] Bruton tyrosine kinase inhibitors (BTKis) are therapeutic agents for relapsed/refractory chronic lymphocytic leukemia (R/R CLL). Previous indirect treatment comparisons are limited in simultaneously comparing multiple intervent…
FULLTEXT: AI-ReML algorithm versus -
Apoptosis-related genes influence prognosis and immune characteristics of diffuse large B-cell lymphoma.
[OBJECTIVES] Dysregulation of apoptosis-related genes (ARGs) may contribute to tumorigenesis and impact patient prognosis, but their specific influence on prognosis and immune characteristics in diffuse large B-cell lymphoma (DLBCL) remains…
FULLTEXT: AI-ReML algorithm versus -
A Randomized Trial Evaluating Intraoperative Ischemic Preconditioning of Parathyroid Glands During Total Thyroidectomy: A Signal for Earlier Parathyroid Function Recovery.
[BACKGROUND] Ischemic preconditioning of parathyroid glands (IPCP) is biologically plausible but clinical evidence is limited. In this single-center randomized trial (ChiCTR2000039788), we compared IPCP versus control during total thyroidec…
FULLTEXT: AI-ReML algorithm versus -
Impact of Adjuvant Chemotherapy on Survival of the Patients with pT1N + M0 Gastric Cancer: A Retrospective Cohort Study.
[BACKGROUND] The advantages of postoperative adjuvant chemotherapy (ACT) for gastric cancer patients with pT1N + M0 staging have been a subject of debate. This study aims to assess whether ACT can enhance the overall survival (OS) of postop…
FULLTEXT: AI-ReML algorithm versus -
Cost-effectiveness of the GAAD algorithm for hepatocellular carcinoma surveillance of patients with compensated cirrhosis: a model-based analysis using Italian real-world data.
[AIMS] Early detection of hepatocellular carcinoma (HCC) in patients with compensated cirrhosis (CC) is critical for improving prognosis. The GAAD algorithm (gender [biological sex], age, alpha-fetoprotein [AFP], protein induced by vitamin …
FULLTEXT: AI-ReML algorithm versus -
Causal Caution Before Declaring Superiority of Liver Resection Versus Radiofrequency Ablation for Very Early-Stage Hepatocellular Carcinoma.
FULLTEXT: AI-ReML algorithm versus
-
Model-based evaluation of colorectal cancer screening effectiveness: three rounds of multitarget stool DNA testing versus one colonoscopy.
[BACKGROUND] Several colorectal cancer (CRC) screening modalities are guideline-recommended in the United States but differ in screening interval and real-world adherence. Accordingly, single-round test performance may not reflect cumulativ…
FULLTEXT: AI-ReML algorithm versus -
Cost of managing brain metastases in ALK-positive advanced NSCLC patients receiving first-line ALK TKIs in China.
[AIM] To estimate brain metastases (BM) management costs in Chinese ALK+ advanced non-small-cell lung cancer (NSCLC) patients receiving first-line (1 L) ALK tyrosine kinase inhibitors (TKIs). [METHODS] A survey of 105 clinical experts acro…
FULLTEXT: AI-ReML algorithm versus -
A Retrospective Comparative Study on the Omission Versus Placement of Chest Drain Following Thoracoscopic Sublobar Resection.
[PURPOSE] This study aims to investigate the clinical applicability of omitting chest drainage tube following thoracoscopic sublobar resection. [METHODS] We gathered data from 1,054 patients who met the inclusion criteria and underwent tho…
FULLTEXT: AI-ReML algorithm versus -
Cost-effectiveness of pembrolizumab plus chemotherapy vs cemiplimab plus chemotherapy for first-line metastatic non-small cell lung cancer: a US payer perspective using a matching-adjusted indirect comparison.
[AIM] Recent clinical guidelines recommend pembrolizumab plus chemotherapy and cemiplimab plus chemotherapy as key first-line treatment options for metastatic non-small cell lung cancer (mNSCLC). We evaluated the cost-effectiveness of these…
FULLTEXT: AI-ReML algorithm versus -
Omission of clinical target volume in radiotherapy for unresectable stage III non-small cell lung cancer: a propensity score matching analysis.
[OBJECTIVE] To investigate the efficacy and adverse reactions of radiotherapy with omitted clinical target volume (CTV) in unresectable stage III non-small cell lung cancer (NSCLC). [METHODS] A total of 423 NSCLC patients admitted to our h…
FULLTEXT: AI-ReML algorithm versus -
Cost-effectiveness analysis of tepotinib vs capmatinib as subsequent therapy in MET exon 14-mutated non-small-cell lung cancer.
[BACKGROUND] This study evaluated the cost-effectiveness of Tepotinib versus Capmatinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with MET Exon 14 Skipping Mutations in China. [METHODS] An economic evaluati…
FULLTEXT: AI-ReML algorithm versus -
Cost-effectiveness of pembrolizumab plus chemotherapy for metastatic non-small cell lung cancer: a head-to-head trial vs. real-world comparison.
[OBJECTIVES] Real-world evidence (RWE) is increasingly used in health technology assessment (HTA) to address uncertainties surrounding the generalizability of randomized clinical trial (RCT) data. Pembrolizumab plus platinum-based chemother…
FULLTEXT: AI-ReML algorithm versus